{"prompt": "['Alliance A171601', '8.0', 'DOSEAND TREATMENT MODIFICATIONS', '8.1 Ancillary Therapy, Concomitant Medications, and Supportive Care', '8.1.1 Patients should not receive any other agent which would be considered treatment for', 'the primary neoplasm or impact the primary endpoint.', '8.1.2 Patients should avoid immunizations with live virus vaccines.', '8.1.3 Patients should receive full supportive care while on this study. This includes blood', 'product support, antibiotic treatment, and treatment of other newly diagnosed or concurrent', 'medical conditions. All blood products and conc omitant medications such as antidiarrheals,', 'analgesics, and/or antiemetics received from the first day of study treatment administration', 'until 30 days after the final dose will be recorded in the medical records.', '8.1.4 Treatment with hormones for breast cancer treatment or other chemotherapeutic', 'agents may not be administered.', '8.1.5 Antiemetics may be used at the discretion of the attending physician, with the exception of', 'steroids above.', '8.1.6 Diarrhea management is per the discretion of the treating physician. Diarrhea could be', 'managed conservatively with medications such as loperamide.', 'Patients with severe diarrhea should be assessed for intravenous hydration and correction of', 'electrolyte imbalances.', '8.1.7 Palliative radiation therapy may not be administered.', 'Patients who require radiation therapy during protocol treatment will be removed from', 'protocol therapy due to disease progression.', '8.1.8 Alliance Policy Concerning the Use of Growth Factors', 'Blood products and growth factors should be utilized as clinically warranted and following', 'institutional policies and recommendations.', 'The use of colony stimulating factors, filgrastim (G-CSF), pegfilgrastim and sargramostim', '(GM-CSF) is discouraged but may be used in patients who have prognostic factors that are', 'predictive of clinical deterioration such as pneumonia, hypotension, multi-organ', 'dysfunction (sepsis syndrome) or fungal infection, as per ASCO guidelines Investigators', 'should use their own discretion in using the CSFs in this setting which must be documented', 'and reported on forms.53', '8.1.9 Hypersensitivity/infusionreactions', 'Treat hypersensitivity and infusion reactions to (drug as per institutional standards.', '8.1.10 CYP3A Inhibitors', 'Chronic concomitant treatment with strong inhibitors of CYP3A is strongly discouraged', 'while on this trial. The following drugs are EXAMPLES of strong inhibitors of CYP3A and', 'are not allowed during treatment with palbociclib.', 'Indinavir', 'Clarithromycin', 'Ketoconazole', 'Grapefruit juice', '33', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', 'Because lists of these agents are constantly changing, please consult and review any drugs', 'for their potential to inhibit CYP3A. Examples of resources that may be utilized include the', 'product information for the individual concomitant drug in question, medical reference texts', \"such as the Physicians' Desk Reference, the FDA website, or your local institution's\", 'pharmacist.', '8.1.11 CYP3A Inducers', 'Chronic concomitant treatment with strong inducers of CYP3A is strongly discouraged', 'while on this trial. The following drugs are EXAMPLES of strong inducers of CYP3A and', 'are not allowed during treatment with palbociclib.', 'Rifampin', 'Carbamazepine', 'Because lists of these agents are constantly changing, please consult and review any drugs', 'for their potential to induce CYP3A. Examples of resources that may be utilized inc lude the', 'product information for the individual concomitant drug in question, medical reference texts', \"such as the Physicians' Desk Reference, the FDA website, or your local institution's\", 'pharmacist.', '8.1.12 CYP2A6 Substrates', 'Chronic concomitant treatment with substrates of CYP2A6 is strongly discouraged while', 'on this trial. The following drugs are EXAMPLES of CYP2A6 substrates and are not', 'allowed during treatment with letrozole.', 'Dexmedetomidine', 'Tegafur', 'Because lists of these agents are constantly changing, please consult and review any drugs', 'for their potential to induce CYP2A6. Examples of resources that may be utilized include', 'the product information for the individual concomitant drug in question, medical reference', \"texts such as the Physicians' Desk Reference, the FDA website, or your local institution's\", 'pharmacist.', '34', 'NCIVersion Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}